OpenLB
Open Library of Bioscience
Advanced Search
Radiology and oncology
Mar 01, 2016;50 (1): 80-6.

Antioxidant defence-related genetic variants are not associated with higher risk of secondary thyroid cancer after treatment of malignancy in childhood or adolescence.

Ana Lina Vodusek, Katja Goricar, Barbara Gazic, Vita Dolzan, Janez Jazbec
Author Information
  1. Ana Lina Vodusek: Department of Radiation Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
  2. Katja Goricar: Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  3. Barbara Gazic: Department of Pathology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
  4. Vita Dolzan: Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  5. Janez Jazbec: Department of Hematology and Oncology, University Children's Hospital, Ljubljana, Slovenia.
PMID: 27069453 DOI: 10.1515/raon-2015-0026

Abstract

BACKGROUND: Thyroid cancer is one of the most common secondary cancers after treatment of malignancy in childhood or adolescence. Thyroid gland is very sensitive to the carcinogenic effect of ionizing radiation, especially in children. Imbalance between pro- and anti-oxidant factors may play a role in thyroid carcinogenesis. Our study aimed to assess the relationship between genetic variability of antioxidant defence-related genes and the risk of secondary thyroid cancer after treatment of malignancy in childhood or adolescence.
PATIENTS AND METHODS: In a retrospective study, we compared patients with childhood or adolescence primary malignancy between 1960 and 2006 that developed a secondary thyroid cancer (cases) with patients (controls), with the same primary malignancy but did not develop any secondary cancer. They were matched for age, gender, primary diagnosis and treatment (especially radiotherapy) of primary malignancy. They were all genotyped for SOD2 p.Ala16Val, CAT c.-262C>T, GPX1 p.Pro200Leu, GSTP1 p.Ile105Val, GSTP1 p.Ala114Val and GSTM1 and GSTT1 deletions. The influence of polymorphisms on occurrence of secondary cancer was examined by McNemar test and Cox proportional hazards model.
RESULTS: Between 1960 and 2006 a total of 2641 patients were diagnosed with primary malignancy before the age of 21 years in Slovenia. Among them 155 developed a secondary cancer, 28 of which were secondary thyroid cancers. No significant differences in the genotype frequency distribution were observed between cases and controls. Additionally we observed no significant influence of investigated polymorphisms on time to the development of secondary thyroid cancer.
CONCLUSIONS: We observed no association of polymorphisms in antioxidant genes with the risk for secondary thyroid cancer after treatment of malignancy in childhood or adolescence. However, thyroid cancer is one of the most common secondary cancers in patients treated for malignancy in childhood or adolescence and the lifelong follow up of these patients is of utmost importance.

Keywords

antioxidant genes genetic polymorphism secondary thyroid cancer

References

  1. Med Pediatr Oncol. 2000 Apr;34(4):256-8 [PMID: 10742062]
  2. Cancer. 2003 May 15;97(10):2397-403 [PMID: 12733137]
  3. Leukemia. 2003 Dec;17(12):2540-2 [PMID: 14523457]
  4. Cancer Genet Cytogenet. 2004 May;151(1):60-7 [PMID: 15120911]
  5. Pediatr Blood Cancer. 2004 Jun;42(7):574-81 [PMID: 15127411]
  6. Cancer. 2004 Sep 15;101(6):1463-72 [PMID: 15368334]
  7. Pharmacogenet Genomics. 2005 May;15(5):311-9 [PMID: 15864132]
  8. Lancet. 2005 Jun 11-17;365(9476):2014-23 [PMID: 15950715]
  9. Biometrics. 1992 Jun;48(2):361-72 [PMID: 1637966]
  10. Arch Otolaryngol Head Neck Surg. 2006 Jul;132(7):756-61 [PMID: 16847185]
  11. J Clin Endocrinol Metab. 2006 Dec;91(12):4798-804 [PMID: 17018661]
  12. Nat Clin Pract Endocrinol Metab. 2007 Oct;3(10):713-20 [PMID: 17893690]
  13. J Endocrinol Invest. 2008 Jun;31(6):542-5 [PMID: 18591888]
  14. Acta Cir Bras. 2008 Nov-Dec;23(6):551-4 [PMID: 19030755]
  15. J Exp Clin Cancer Res. 2009 Apr 01;28:46 [PMID: 19338664]
  16. Surgery. 2009 May;145(5):508-13 [PMID: 19375609]
  17. Pediatr Hematol Oncol. 2009 Jun;26(4):240-51 [PMID: 19437326]
  18. Eur J Cancer. 2009 Nov;45(16):2874-81 [PMID: 19467856]
  19. Clin Exp Rheumatol. 2009 Mar-Apr;27(2):229-36 [PMID: 19473562]
  20. Head Neck. 2010 Jun;32(6):750-6 [PMID: 19998441]
  21. Clin Biochem. 2010 May;43(7-8):650-4 [PMID: 20171198]
  22. DNA Repair (Amst). 2010 Jun 4;9(6):604-16 [PMID: 20399712]
  23. Radiat Res. 2010 Dec;174(6):741-52 [PMID: 21128798]
  24. Carcinogenesis. 2011 Oct;32(10):1507-11 [PMID: 21803734]
  25. Endocr Relat Cancer. 2011 Dec 01;18(6):773-82 [PMID: 22002574]
  26. Endocr Relat Cancer. 2012 Jan 09;19(1):C7-11 [PMID: 22143496]
  27. J Mol Endocrinol. 2012 Mar 29;48(3):193-202 [PMID: 22331172]
  28. Cancer Epidemiol. 2012 Dec;36(6):e333-40 [PMID: 22765906]
  29. Radiol Oncol. 2010 Sep;44(3):187-93 [PMID: 22933914]
  30. Radiol Oncol. 2012 Mar;46(1):46-53 [PMID: 22933979]
  31. Mol Biol Rep. 2013 Feb;40(2):1801-12 [PMID: 23073788]
  32. Thyroid Res. 2012 Dec 27;5(1):25 [PMID: 23270549]
  33. J Clin Endocrinol Metab. 2013 Oct;98(10):E1645-54 [PMID: 23666977]
  34. Asian Pac J Cancer Prev. 2013;14(3):1937-43 [PMID: 23679296]
  35. Tumour Biol. 2014 Jan;35(1):759-64 [PMID: 24037914]
  36. Acta Chim Slov. 2010 Mar;57(1):182-8 [PMID: 24061671]
  37. Ann Acad Med Stetin. 2013;59(2):18-28 [PMID: 25026746]
  38. J Radiat Res. 2014 Sep;55(5):885-901 [PMID: 25037101]
  39. Pathol Oncol Res. 2015 Apr;21(2):433-7 [PMID: 25248722]
  40. Tumour Biol. 2015 Feb;36(2):909-14 [PMID: 25307973]
  41. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):178-86 [PMID: 25315963]
  42. Radiol Oncol. 2014 Nov 05;48(4):348-53 [PMID: 25435847]
  43. Oxid Med Cell Longev. 2014;2014:875861 [PMID: 25436036]
  44. J Med Biochem. 2015 Apr;34(2):200-206 [PMID: 28356832]
Journal Article

Word Cloud

Created with Highcharts 10.0.0secondarycancermalignancythyroidchildhoodadolescencetreatmentpatientsprimarypcancersgeneticantioxidantgenesriskpolymorphismsobservedThyroidonecommonespeciallystudydefence-related19602006developedcasescontrolsageGSTP1influencesignificantBACKGROUND:glandsensitivecarcinogeniceffectionizingradiationchildrenImbalancepro-anti-oxidantfactorsmayplayrolecarcinogenesisaimedassessrelationshipvariabilityPATIENTSANDMETHODS:retrospectivecompareddevelopmatchedgenderdiagnosisradiotherapygenotypedSOD2Ala16ValCATc-262C>TGPX1Pro200LeuIle105ValAla114ValGSTM1GSTT1deletionsoccurrenceexaminedMcNemartestCoxproportionalhazardsmodelRESULTS:total2641diagnosed21yearsSloveniaAmong15528differencesgenotypefrequencydistributionAdditionallyinvestigatedtimedevelopmentCONCLUSIONS:associationHowevertreatedlifelongfollowutmostimportanceAntioxidantvariantsassociatedhigherpolymorphism

Similar Articles

Cited By (1)